SOUTH AFRICA – Pharmaceutical manufacturer Adcock Ingram is pursuing potential acquisitions to expand its range of products that are not subject to government price controls.
This comes as the company is faces increasing margin pressure on its portfolio of medicines governed by the health department’s Single Exit Price regulations, after health minister Joe Phaahla announced a below-inflation price hike for 2023.
The Single Exit Price regulations control prices at every step of the supply chain, from factory gate to pharmacy checkout, and permit an annual price hike which the minister this year set at 3.28%.
“If we are going to sustain margins and be able to cope with cost input pressures, we have to keep building our non-regulated portfolio,” CEO of Adcock Andy Hall said when the company released its interim results for the six months to December 31.
Margin compression on price-regulated products was as much of a worry as the state of the SA economy and load-shedding, he said.
The below-inflation increase caught the pharmaceutical industry on the back foot, as it was about half the level it had anticipated based on a formula set out in the Single Exit Price regulations.
Previous Single Exit Price increases have been broadly in line with the consumer price index (CPI), which came in at 6.9% in January.
More than half (56%) of Adcock Ingram’s portfolio by revenue was comprised of medicines subject to the Single Exit Price, said Hall. “It’s the vast majority of prescription and the majority of our over-the-counter and hospital products.”
Pharmaceutical Task Group to intervene
SA’s umbrella association for drug manufacturers, the Pharmaceutical Task Group, has written to the medicines pricing committee that advises the minister to ask for an explanation of this year’s adjustment.
“In our view it is not reflective of consumer price inflation or the formula previously used in the regulations,” said Hall, adding he was not optimistic the figure would be changed.
Adcock Ingram has four divisions — prescription medicines, over-the-counter medicines, hospital products, and consumer goods such as baby wipes and sunblock.
In line with many other large manufacturers, including rival Aspen Pharmacare, Adcock Ingram has negotiated with local municipalities to minimise power cuts to its facilities.
For example, Johannesburg City Power had exempted Adcock Ingram’s Aeroton plant from load-shedding, said Hall. However, the site, which makes hospital products such as intravenous drips, remains vulnerable to electricity infrastructure failures, which have a knock-on effect on water supplies.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
